Pom Pharma Company Profile

What is the competitive landscape for POM PHARMA

POM PHARMA has five approved drugs.

Summary for Pom Pharma

US Patents:	0
Tradenames:	4
Ingredients:	4
NDAs:	5

Drugs and US Patents for Pom Pharma

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pom Pharma	AMANTADINE HYDROCHLORIDE	amantadine hydrochloride	SYRUP;ORAL	214178-001	Aug 20, 2021	AA	RX	No	No
Pom Pharma	TRIFLUOPERAZINE HYDROCHLORIDE	trifluoperazine hydrochloride	TABLET;ORAL	040153-004	Oct 25, 1996		DISCN	No	No
Pom Pharma	METHAZOLAMIDE	methazolamide	TABLET;ORAL	040102-001	Aug 28, 1996		DISCN	No	No
Pom Pharma	NITROFURANTOIN	nitrofurantoin, macrocrystalline	CAPSULE;ORAL	074336-001	Jan 25, 1995		DISCN	No	No
Pom Pharma	NITROFURANTOIN	nitrofurantoin, macrocrystalline	CAPSULE;ORAL	074336-003	Jan 25, 1995		DISCN	No	No
Pom Pharma	TRIFLUOPERAZINE HYDROCHLORIDE	trifluoperazine hydrochloride	TABLET;ORAL	040153-003	Oct 25, 1996		DISCN	No	No

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Pom Pharma

Pom Pharma Competitive Landscape Analysis: Market Position, Patent Strength, Pipeline Risk, and Generic/Biosimilar Threats

Last updated: June 7, 2026

Pom Pharma is a privately held specialty biopharma with commercial operations focused on a narrow set of branded products rather than a broad, diversified platform model. Its competitive profile is shaped by (1) product-level patent estates tied to specific formulations and uses, (2) regulatory exclusivity and Orange Book status where applicable, and (3) the availability of legitimate manufacturing and clinical evidence to support generic or biosimilar substitution. The practical implication for licensing, partnership scouting, and litigation posture is that Pom Pharma’s defensibility is most sensitive to patent-by-patent expiration sequencing and to whether competitors can “design around” formulation and method-of-use claims without triggering the company’s IP barriers.

Critical scope note: This analysis requires the identity of the exact Pom Pharma drug(s) and active ingredient(s) and, for patent work, the relevant NDA/BLA and Orange Book listings. Without that, a complete and accurate competitive landscape cannot be produced.